MarNav Services
A Woman Owned Service Disabled Veteran Owned Small Business
With service offerings in personal protective equipment, logistics, and petroleum products.
A Woman Owned Service Disabled Veteran Owned Small Business
With service offerings in personal protective equipment, logistics, and petroleum products.
A rapid test for the qualitative detection of novel coronavirus SARS-CoV-2 antigen in nasopharyngeal swab. A rapid chromatographic immunoassay intended for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in direct nasopharyngeal swab (NP) specimens from individuals who are suspected of COVID-19 by their healthcare provider within the first six days of symptom onset. FDA approved under Emergency Use Authorization.
Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. ยง263a, that meet the requirements to perform moderate complexity, high complexity, or waived tests. This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.